TACSTD2 and esophageal squamous cell carcinoma: The IHC results revealed that the treatments did not alter the expression of TROP2 in three ESCC PDX models (Fig. 8E), demonstrating that IMMU exerted antitumor effects in a TROP2-dependent matter.